US 2023/0055694 A1Published application

Receptors providing targeted costimulation for adoptive cell therapy

OwnerJohn Bridgeman, Robert Hawkins +3inventors

InventorsJohn Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou

Life of this patent

Estimating the term…

Abstract

Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.

Claims30

Dependent claims

1-43. (canceled)

A chimeric costimulatory antigen receptor (CoStAR) which comprises:

an extracellular binding domain that binds to mesothelin (MSLN);
a transmembrane domain;
a CD28 signaling domain, wherein the CD28 signaling domain comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain comprises any one of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(l) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

66 more elements

A cell which expresses a CoStAR, the CoStAR comprising:

an extracellular binding domain that binds to mesothelin (MSLN);
a CD28 signaling domain, wherein the CD28 signaling domain comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain comprises any one of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(l) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

65 more elements

A fusion protein, wherein the fusion protein comprises:

i. a first sequence, wherein the first sequence comprises one or more of:
a. a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
b. a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
c. a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
d. a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
e. a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
f. a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
g. a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
h. a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
i. a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
j. a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
k. a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(a) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191;
ii. a second sequence that is a transmembrane domain;
iii. a third sequence that comprises the amino acid sequence of SEQ ID NO:
25;
and
iv. a fourth sequence that comprises the amino acid sequence of SEQ ID NO:
32, wherein the first sequence is linked to the second sequence, wherein the second sequence is linked to the third sequence, and wherein the third sequence is linked to the fourth sequence.

65 more elements

A method of cell therapy comprising:

a) identifying a subject, wherein the subject has cancer that expresses MSLN;
and
b) administering any a CoStAR that comprises:
an extracellular binding domain that binds to mesothelin (MSLN),
a transmembrane domain,
a CD28 signaling domain that comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain is linked to the transmembrane domain, wherein the transmembrane domain is linked to the CD28 signaling domain, wherein the CD28 signaling domain is linked to the CD40 domain, and
wherein the extracellular binding domain comprises any one or more of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(1) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

70 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/936,102Filed 28 Sep 2022
Priority: 16 Jun 2021
Published: 23 Feb 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification31 codes

C07K 16/3007
From tumour cells: carcino-embryonic Antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/4255
Adhesion molecules, e.g. NRCAM, EpCAM or cadherins: mesothelin [MSLN]

Family

Application63/211,046Us provisional application · filed 16 Jun 2021
Application63/211,042Us provisional application · filed 16 Jun 2021
Application63/222,913Us provisional application · filed 16 Jul 2021
Application63/301,340Us provisional application · filed 20 Jan 2022
Application17/807,109Continuation · filed 15 Jun 2022
Application17/936,102Continuation
US 11,945,876 B2Related patent
US 2023/0002504 A1Published application
US 2023/0055694 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results

US 2023/0055694 A1Published application

Receptors providing targeted costimulation for adoptive cell therapy

OwnerJohn Bridgeman, Robert Hawkins +3inventors

InventorsJohn Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou

Life of this patent

Estimating the term…

Abstract

Claims30

Dependent claims

1-43. (canceled)

A chimeric costimulatory antigen receptor (CoStAR) which comprises:

an extracellular binding domain that binds to mesothelin (MSLN);
a transmembrane domain;
a CD28 signaling domain, wherein the CD28 signaling domain comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain comprises any one of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(l) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

66 more elements

A cell which expresses a CoStAR, the CoStAR comprising:

an extracellular binding domain that binds to mesothelin (MSLN);
a CD28 signaling domain, wherein the CD28 signaling domain comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain comprises any one of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(l) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

65 more elements

A fusion protein, wherein the fusion protein comprises:

i. a first sequence, wherein the first sequence comprises one or more of:
a. a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
b. a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
c. a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
d. a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
e. a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
f. a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
g. a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
h. a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
i. a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
j. a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
k. a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(a) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191;
ii. a second sequence that is a transmembrane domain;
iii. a third sequence that comprises the amino acid sequence of SEQ ID NO:
25;
and
iv. a fourth sequence that comprises the amino acid sequence of SEQ ID NO:
32, wherein the first sequence is linked to the second sequence, wherein the second sequence is linked to the third sequence, and wherein the third sequence is linked to the fourth sequence.

65 more elements

A method of cell therapy comprising:

a) identifying a subject, wherein the subject has cancer that expresses MSLN;
and
b) administering any a CoStAR that comprises:
an extracellular binding domain that binds to mesothelin (MSLN),
a transmembrane domain,
a CD28 signaling domain that comprises the amino acid sequence of SEQ ID NO:
25;
and
a CD40 signaling domain, wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO:
32,
wherein the extracellular binding domain is linked to the transmembrane domain, wherein the transmembrane domain is linked to the CD28 signaling domain, wherein the CD28 signaling domain is linked to the CD40 domain, and
wherein the extracellular binding domain comprises any one or more of:
(a) a HCDR1 that is an HCDR1 in SEQ ID NO:
186, a HCDR2 that is an HCDR2 in SEQ ID NO:
186, a HCDR3 that is an HCDR3 in SEQ ID NO:
186, a LCDR1 that is an LCDR1 in SEQ ID NO:
186, a LCDR2 that is an LCDR2 in SEQ ID NO:
186, and LCDR3 that is an LCDR3 in SEQ ID NO:
186;
(b) a HCDR1 that is an HCDR1 in SEQ ID NO:
187, a HCDR2 that is an HCDR2 in SEQ ID NO:
187, a HCDR3 that is an HCDR3 in SEQ ID NO:
187, a LCDR1 that is an LCDR1 in SEQ ID NO:
187, a LCDR2 that is an LCDR2 in SEQ ID NO:
187, and LCDR3 that is an LCDR3 in SEQ ID NO:
187;
(c) a HCDR1 that is an HCDR1 in SEQ ID NO:
188, a HCDR2 that is an HCDR2 in SEQ ID NO:
188, a HCDR3 that is an HCDR3 in SEQ ID NO:
188, a LCDR1 that is an LCDR1 in SEQ ID NO:
188, a LCDR2 that is an LCDR2 in SEQ ID NO:
188, and LCDR3 that is an LCDR3 in SEQ ID NO:
188;
(d) a HCDR1 that is an HCDR1 in SEQ ID NO:
189, a HCDR2 that is an HCDR2 in SEQ ID NO:
189, a HCDR3 that is an HCDR3 in SEQ ID NO:
189, a LCDR1 that is an LCDR1 in SEQ ID NO:
189, a LCDR2 that is an LCDR2 in SEQ ID NO:
189, and LCDR3 that is an LCDR3 in SEQ ID NO:
189;
(e) a HCDR1 that is an HCDR1 in SEQ ID NO:
190, a HCDR2 that is an HCDR2 in SEQ ID NO:
190, a HCDR3 that is an HCDR3 in SEQ ID NO:
190, a LCDR1 that is an LCDR1 in SEQ ID NO:
190, a LCDR2 that is an LCDR2 in SEQ ID NO:
190, and LCDR3 that is an LCDR3 in SEQ ID NO:
190;
(f) a HCDR1 that is an HCDR1 in SEQ ID NO:
191, a HCDR2 that is an HCDR2 in SEQ ID NO:
191, a HCDR3 that is an HCDR3 in SEQ ID NO:
191, a LCDR1 that is an LCDR1 in SEQ ID NO:
191, a LCDR2 that is an LCDR2 in SEQ ID NO:
191, and LCDR3 that is an LCDR3 in SEQ ID NO:
191;
(g) a VH that is a VH in SEQ ID NO:
186, and a VL that is a VL in SEQ ID NO:
186;
(h) a VH that is a VH in SEQ ID NO:
187, and a VL that is a VL in SEQ ID NO:
187;
(i) a VH that is a VH in SEQ ID NO:
188, and a VL that is a VL in SEQ ID NO:
188;
(j) a VH that is a VH in SEQ ID NO:
189, and a VL that is a VL in SEQ ID NO:
189;
(k) a VH that is a VH in SEQ ID NO:
190, and a VL that is a VL in SEQ ID NO:
190;
or
(1) a VH that is a VH in SEQ ID NO:
191, and a VL that is a VL in SEQ ID NO:
191.

70 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/936,102Filed 28 Sep 2022
Priority: 16 Jun 2021
Published: 23 Feb 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification31 codes

C07K 16/3007
From tumour cells: carcino-embryonic Antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/4255
Adhesion molecules, e.g. NRCAM, EpCAM or cadherins: mesothelin [MSLN]

Family

Application63/211,046Us provisional application · filed 16 Jun 2021
Application63/211,042Us provisional application · filed 16 Jun 2021
Application63/222,913Us provisional application · filed 16 Jul 2021
Application63/301,340Us provisional application · filed 20 Jan 2022
Application17/807,109Continuation · filed 15 Jun 2022
Application17/936,102Continuation
US 11,945,876 B2Related patent
US 2023/0002504 A1Published application
US 2023/0055694 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key